Pharma Competitors

OTC Stocks . USA . 
Stock . Pharma Bio Serv
PBSV Stock  USD 0.54  0.08  17.39%   
Pharma Bio Serv competes with PreAxia Health, Vynleads, and Unidoc Health; as well as few others. The company conducts business under Life Sciences Tools & Services sector and is part of Health Care industry. Analyzing Pharma Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Pharma Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Pharma Bio Correlation with its peers.

Pharma Bio vs Medibio Correlation

Very weak diversification

The correlation between Pharma Bio Serv and MDBIF is 0.41 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pharma Bio Serv and MDBIF in the same portfolio, assuming nothing else is changed.

Moving against Pharma OTC Stock

  0.51CVX Chevron Corp Earnings Call TomorrowPairCorr
  0.42XOM Exxon Mobil Corp Earnings Call TomorrowPairCorr
  0.41BA BoeingPairCorr
  0.39BKRKY Bank RakyatPairCorr
  0.34CAT Caterpillar Earnings Call TodayPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pharma Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.030.545.13
Details
Intrinsic
Valuation
LowRealHigh
0.020.455.04
Details
Naive
Forecast
LowNextHigh
0.010.525.11
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
0.470.540.61
Details

Pharma Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pharma Bio and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Pharma and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pharma Bio Serv does not affect the price movement of the other competitor.

High positive correlations

SPLTF
+ 1.0
PAXH
MDBIF
+ 0.78
ANPCY
MDBIF
+ 0.66
UDOCF
ANPCY
+ 0.58
UDOCF
MDBIF
+ 0.54
EMOR
NUMIF
+ 0.5
SRBCF
  

High negative correlations

SRBCF
- 0.8
VYND
ANPCY
- 0.72
VPTDF
UDOCF
- 0.61
VPTDF
NUMIF
- 0.58
VYND
MDBIF
- 0.53
VPTDF
MDBIF
- 0.48
VYND

Risk-Adjusted Indicators

There is a big difference between Pharma OTC Stock performing well and Pharma Bio OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pharma Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PAXH  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
VYND  0.84  0.41  0.00  6.15  0.00 
 0.00 
 0.00 
 0.00 
 28.00 
VPTDF  4.36  0.58  0.10  3.31  4.43 
(5.22)
 10.99 
(8.20)
 22.71 
SRBCF  149.26  86.05  0.00 (0.41) 0.00 
 0.00 
 0.00 
 0.00 
 5,000 
SPLTF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
UDOCF  7.31 (0.05) 0.00  0.14  0.00 
 0.00 
 15.38 
(15.38)
 48.08 
EMOR  12.17  1.26  0.06  25.56  13.29 
(19.53)
 36.36 
(25.19)
 75.19 
ANPCY  10.80 (0.65) 0.00 (0.93) 0.00 
 0.00 
 34.78 
(26.67)
 145.07 
NUMIF  8.14  0.38  0.02 (0.43) 8.69 
(13.13)
 25.00 
(17.50)
 68.91 
MDBIF  3.52 (1.98) 0.00 (0.75) 0.00 
 0.00 
 0.00 
 0.00 
 84.08 

Pharma Bio Competitive Analysis

The better you understand Pharma Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pharma Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pharma Bio's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
PBSV PAXH VYND VPTDF SRBCF SPLTF UDOCF EMOR ANPCY NUMIF
 17.39 
 0.54 
Pharma
 0.00 
 0.22 
PreAxia
 0.00 
 0.32 
Vynleads
 4.22 
 0.1 
VentriPoint
 0.00 
 0.01 
Sirona
 0.00 
 0.08 
SpotLite360
 8.33 
 0.11 
Unidoc
 2.99 
 0.01 
Healixa
 0.00 
 0.07 
Angle
 4.29 
 0.03 
Numinus
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Out of control
Out of control
Out of control
Very steady
Out of control
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Weak
Weakest
Fair
Fair
Fair
Weakest
Weakest
Fair
Weakest
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Small
Strong
Small
Low
Low
Low
Low
Low
Strong
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Not Rated
Strong Sell
Current Ratio
9.07
N/A
0.05
6.74
2.6
0.74
N/A
N/A
6.55
16.08
Net Asset
20.65 M
259
25.39 K
9.54 M
1.29 M
7.75 M
1.18 M
N/A
47.31 M
52.63 M
Profit Margin
0.0519
N/A
N/A
N/A
N/A
-0.29
N/A
N/A
N/A
N/A
EBITDA
1.23 M
(180.64 K)
(260.52 K)
(3.82 M)
(2.3 M)
(3.59 M)
N/A
N/A
(15.72 M)
(42.85 M)
Operating Margin
0.0606
N/A
N/A
-124.5
-4.92
-0.12
N/A
N/A
-16.23
-2.63
Current Valuation
4.87 M
2.81 M
3.48 M
28.27 M
24.5 M
9.77 M
5.98 M
N/A
145.22 M
20.07 M
Price To Book
1.15
N/A
N/A
8.27
36.93
1.44
328.68
N/A
4.2
1.31
Retained Earnings
20.5 M
(3.75 M)
N/A
(20.43 M)
(12.03 M)
N/A
N/A
N/A
(41.22 M)
N/A
Current Asset
22.27 M
4 K
N/A
1.07 M
1.49 M
N/A
N/A
N/A
7.23 M
N/A
Beta
0.36
-0.3
0.41
0.28
-0.36
N/A
N/A
N/A
0.43
2.03
Number Of Employees
140
3
1
17
12
2
3
3
128
10
Shares Outstanding
22.95 M
19.77 M
11.6 M
156.51 M
251.73 M
115.42 M
10.93 M
77.99 M
26.06 M
262.75 M
Cash Flow From Operations
592.46 K
(63.97 K)
(130.51 K)
(3.15 M)
(2.16 M)
(2.44 M)
N/A
N/A
(14.01 M)
(26.23 M)
Annual Yield
0.0581
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Debt
520.77 K
1.74 M
250.25 K
125.38 K
468.77 K
196.57 K
N/A
N/A
5.24 M
213.15 K
Return On Equity
0.0568
N/A
N/A
-1.35
-35.56
-0.38
N/A
N/A
-0.56
-0.99
Z Score
24.0
N/A
-15.0
N/A
10.5
21.0
N/A
N/A
10.2
N/A
Return On Asset
0.033
-782.99
-7.04
-0.64
-1.35
-0.1
N/A
N/A
-0.3
-0.33
Book Value Per Share
0.72
-0.11
-0.051
0.034
0.004
0.087
N/A
N/A
1.36
0.14
Current Liabilities
1.67 M
1.61 M
N/A
3.05 M
801 K
N/A
N/A
N/A
2.2 M
N/A
Total Asset
20.65 M
259
25.39 K
9.54 M
1.29 M
7.75 M
1.18 M
N/A
47.31 M
52.63 M
Debt To Equity
0.032
N/A
N/A
0.022
0.6
0.019
N/A
N/A
0.16
0.12
Target Price
1.77
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.5
Shares Owned By Institutions
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
2.88
Market Capitalization
20.88 M
1.12 M
7.66 M
32.09 M
20.74 M
6.91 M
5.64 M
15.6 M
92.38 M
49.17 M
Price To Earning
10.0
-50.0
N/A
68.0
-7.33
N/A
N/A
N/A
N/A
N/A
Price To Sales
0.9
3415.52
65100.92
897.04
36.46
0.74
N/A
N/A
144.24
6.38
Net Income
1.01 M
(180.64 K)
(271.58 K)
(3.88 M)
(2.31 M)
(4.01 M)
N/A
N/A
(15.01 M)
(44.88 M)
Earnings Per Share
0.04
-0.009
-0.024
-0.018
-0.012
-0.074
N/A
N/A
-0.82
-0.098
Shares Owned By Insiders
64.53
46.03
43.13
1.75
10.43
1.64
20.12
N/A
N/A
4.79
Revenue
19.4 M
368
484
N/A
268.02 K
204.63 K
N/A
N/A
1.01 M
6.49 M
Working Capital
20.6 M
(1.61 M)
N/A
(1.99 M)
692 K
N/A
N/A
N/A
5.03 M
N/A
Cash And Equivalents
14.24 M
200
1.72 K
7.29 M
1.13 M
1.37 M
N/A
N/A
20.5 M
41.79 M
Cash Per Share
0.62
N/A
N/A
0.05
N/A
0.01
N/A
N/A
0.87
0.17
Gross Profit
4.88 M
368
(31.98 K)
(6.27 K)
199.25 K
N/A
N/A
N/A
54 K
1.78 M
Day Typical Price
0.54
0.22
0.32
0.0964
0.0051
0.078
0.11
0.0131
0.067
0.0335
Accumulation Distribution
N/A
N/A
N/A
N/A
N/A
N/A
0.0833
0.0299
N/A
42.28
Market Facilitation Index
N/A
N/A
N/A
N/A
N/A
N/A
0.01
4.0E-4
N/A
N/A
Daily Balance Of Power
9.2 T
0.0
0.0
9.2 T
0.0
0.0
(1.00)
(1.00)
0.0
(15.00)
Period Momentum Indicator
0.08
N/A
N/A
0.0039
N/A
N/A
(0.01)
(0.0004)
N/A
(0)
Rate Of Daily Change
1.17
1.0
1.0
1.04
1.0
1.0
0.92
0.97
1.0
0.96
Day Median Price
0.54
0.22
0.32
0.0964
0.0051
0.078
0.12
0.0132
0.067
0.0335
Price Action Indicator
0.04
N/A
N/A
0.002
N/A
N/A
(0.01)
(0.0004)
N/A
(0.0008)
Relative Strength Index
50.3
N/A
100.0
54.24
32.89
N/A
46.22
50.98
39.24
47.85
Coefficient Of Variation
4465.64
N/A
812.4
934.7
829.23
N/A
(12,278)
1398.34
(3,390)
3421.81
Mean Deviation
2.19
N/A
0.8356
4.36
149.26
N/A
7.31
12.17
10.8
8.14
Jensen Alpha
0.0436
N/A
0.4099
0.5825
86.05
N/A
(0.05)
1.26
(0.65)
0.3836
Total Risk Alpha
(0.31)
N/A
0.1101
0.0958
19.91
N/A
(0.97)
(0.31)
(2.40)
(0.70)
Sortino Ratio
0.0036
N/A
N/A
0.1045
N/A
N/A
N/A
0.0619
N/A
0.0242
Downside Variance
61.44
N/A
N/A
25.62
N/A
N/A
N/A
375.54
N/A
123.5
Standard Deviation
4.59
N/A
3.45
5.65
615.77
N/A
9.92
17.83
20.32
11.76
Kurtosis
5.23
N/A
66.0
(0.23)
65.95
N/A
0.4629
1.18
13.83
2.39
Potential Upside
8.0
N/A
N/A
10.99
N/A
N/A
15.38
36.36
34.78
25.0
Treynor Ratio
0.1224
N/A
6.15
3.31
(0.41)
N/A
0.1441
25.56
(0.93)
(0.43)
Maximum Drawdown
25.93
N/A
28.0
22.71
5000.0
N/A
48.08
75.19
145.07
68.91
Variance
21.06
N/A
11.88
31.89
379167.3
N/A
98.32
318.0
412.82
138.36
Market Risk Adjusted Performance
0.1324
N/A
6.16
3.32
(0.40)
N/A
0.1541
25.57
(0.92)
(0.42)
Risk Adjusted Performance
0.0249
N/A
0.0984
0.0874
0.0987
N/A
0.0033
0.0622
(0.01)
0.0309
Skewness
0.4789
N/A
8.12
0.3479
8.12
N/A
0.1923
0.6583
2.83
0.9241
Semi Deviation
3.31
N/A
N/A
4.43
N/A
N/A
N/A
13.29
N/A
8.69
Information Ratio
0.0061
N/A
0.1014
0.0937
0.1205
N/A
(0.02)
0.0673
(0.03)
0.0229
Value At Risk
(6.90)
N/A
N/A
(8.20)
N/A
N/A
(15.38)
(25.19)
(26.67)
(17.50)
Expected Short fall
(6.78)
N/A
N/A
(5.22)
N/A
N/A
N/A
(19.53)
N/A
(13.13)
Downside Deviation
7.84
N/A
N/A
5.06
N/A
N/A
N/A
19.38
N/A
11.11
Semi Variance
10.95
N/A
N/A
19.62
N/A
N/A
N/A
176.54
N/A
75.43

Pharma Bio Competition Performance Charts

Five steps to successful analysis of Pharma Bio Competition

Pharma Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pharma Bio Serv in relation to its competition. Pharma Bio's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Pharma Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pharma Bio's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pharma Bio Serv, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Pharma Bio position

In addition to having Pharma Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cash Cows Thematic Idea Now

Cash Cows
Cash Cows Theme
Entities with stable and reliable earnings or profits, which allows them to pay consistent dividends to their shareholders. The Cash Cows theme has 25 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cash Cows Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Pharma OTC Stock Analysis

When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY